These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11756100)

  • 1. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability.
    Tombach B; Bremer C; Reimer P; Matzkies F; Schaefer RM; Ebert W; Geens V; Eisele J; Heindel W
    AJR Am J Roentgenol; 2002 Jan; 178(1):105-9. PubMed ID: 11756100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study.
    Tombach B; Bremer C; Reimer P; Kisters K; Schaefer RM; Geens V; Heindel W
    Radiology; 2001 Mar; 218(3):651-7. PubMed ID: 11230635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].
    Vogl TJ; Friebe CE; Balzer T; Mack MG; Steiner S; Schedel H; Pegios W; Lanksch W; Banzer D; Felix R
    Radiologe; 1995 Aug; 35(8):508-16. PubMed ID: 7568795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.
    Hahn G; Sorge I; Gruhn B; Glutig K; Hirsch W; Bhargava R; Furtner J; Born M; Schröder C; Ahlström H; Kaiser S; Moritz JD; Kunze CW; Shroff M; Stokland E; Trnkova ZJ; Schultze-Mosgau M; Reif S; Bacher-Stier C; Mentzel HJ
    Invest Radiol; 2009 Dec; 44(12):776-83. PubMed ID: 19858730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dialysability of gadoteric acid in patients with end-stage renal disease undergoing hemodialysis.
    Gheuens E; Daelemans R; Mesens S
    Invest Radiol; 2014 Aug; 49(8):505-8. PubMed ID: 24619209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
    Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
    Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure.
    Tombach B; Bremer C; Reimer P; Schaefer RM; Ebert W; Geens V; Heindel W
    Invest Radiol; 2000 Jan; 35(1):35-40. PubMed ID: 10639034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
    Voth M; Rosenberg M; Breuer J
    Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative assessment of glomerular filtration rate with MR gadolinium slope clearance measurements: a phase I trial.
    Boss A; Martirosian P; Gehrmann M; Artunc F; Risler T; Oesingmann N; Claussen CD; Schick F; Küper K; Schlemmer HP
    Radiology; 2007 Mar; 242(3):783-90. PubMed ID: 17209166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
    Hammerstingl R; Adam G; Ayuso JR; Van Beers B; Belfiore G; Bellin MF; Bongartz G; Ernst O; Frericks B; Giuseppetti G; Heinz-Peer G; Laghi A; Martin J; Pering C; Reimer P; Richter GM; Roemer FW; Schäfer FK; Vilgrain V; Vogl TJ; Weishaupt D; Wall A; Zech CJ; Tombach B
    Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast material for abdominal dynamic contrast-enhanced 3D MR angiography with parallel imaging: intraindividual equimolar comparison of a macrocyclic 1.0 M gadolinium chelate and a linear ionic 0.5 M gadolinium chelate.
    Hadizadeh DR; Von Falkenhausen M; Kukuk GM; Schöneseiffen K; Gieseke J; Schild HH; Willinek WA
    AJR Am J Roentgenol; 2010 Mar; 194(3):821-9. PubMed ID: 20173166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-resolved contrast-enhanced three-dimensional pulmonary MR-angiography: 1.0 M gadobutrol vs. 0.5 M gadopentetate dimeglumine.
    Fink C; Bock M; Kiessling F; Lichy MP; Krissak R; Zuna I; Schmähl A; Delorme S; Kauczor HU
    J Magn Reson Imaging; 2004 Feb; 19(2):202-8. PubMed ID: 14745754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients.
    Schieren G; Tokmak F; Lefringhausen L; van Bracht M; Perings C; Willers R; Günsel A; Kemper F; Wiesmüller GA; Rump LC
    Am J Kidney Dis; 2008 Jun; 51(6):976-86. PubMed ID: 18501785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine.
    Anzalone N; Gerevini S; Scotti R; Vezzulli P; Picozzi P
    Acta Radiol; 2009 Oct; 50(8):933-40. PubMed ID: 19626475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol.
    Tombach B; Benner T; Reimer P; Schuierer G; Fallenberg EM; Geens V; Wels T; Sorensen AG
    Radiology; 2003 Mar; 226(3):880-8. PubMed ID: 12601217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers.
    Staks T; Schuhmann-Giampieri G; Frenzel T; Weinmann HJ; Lange L; Platzek J
    Invest Radiol; 1994 Jul; 29(7):709-15. PubMed ID: 7960618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normal dynamic MRI enhancement patterns of the upper abdominal organs: gadoxetic acid compared with gadobutrol.
    Kühn JP; Hegenscheid K; Siegmund W; Froehlich CP; Hosten N; Puls R
    AJR Am J Roentgenol; 2009 Nov; 193(5):1318-23. PubMed ID: 19843748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine.
    Durmus T; Schilling R; Doeblin P; Huppertz A; Hamm B; Taupitz M; Wagner M
    Invest Radiol; 2012 Mar; 47(3):183-8. PubMed ID: 22183078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of glomerular filtration rate using dynamic magnetic resonance imaging in patients with chronic kidney disease.
    Artunc F; Yildiz S; Boss A; Frenzel T; Schlemmer HP; Schick F; Risler T; Häring HU; Rossi C
    J Nephrol; 2011; 24(4):482-9. PubMed ID: 21058262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.